title: Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach.
abstract: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II(1), age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II(1); 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92%, 95% confidence interval: 82-98%) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94%, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option.
authors.affiliation: Radiation Oncology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. sishikur-ncche@umin.ac.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishikura
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohtsu
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Ichiro
authors.initials: I
authors.lastname: Oda
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takagi
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Mera
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kagami
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Itoh
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Tamaki
authors.forename: Junji
authors.initials: J
authors.lastname: Suzumiya
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone